In the specification:

Please amend the specification by adding the following passage at page 3, after line 14 and before line 15:

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows construct cassettes cloned into pBluescript KS+®.

Figure 2 shows oligonucleotide sequences for chimeric receptor construction. Oligonucleotides are presented in 5' and 3' orientation and are as follows: S4501 (SEQ ID NO: 1); S4502 (SEQ ID NO: 2); S4503 (SEQ ID NO: 3); S4504 (SEQ ID NO: 4); S4881 (SEQ ID NO: 5); S4882 (SEQ ID NO: 6); S4883 (SEQ ID NO: 7); S4884 (SEQ ID NO: 8); S4885 (SEQ ID NO: 9); S4886 (SEQ ID NO: 10); S4499 (SEQ ID NO: 11); S4500 (SEQ ID NO: 12); S4700 (SEQ ID NO: 13); and S4701 (SEQ ID NO: 14).

Figure 3 shows double gene expression plasmids for separate chain chimeric receptors, including: pHMF367; pHMF370; and pHMF374.

Figure 4 shows a histogram revealing stimulation of separate chain receptors with HL60 target cells.

Figure 5 shows a histogram revealing stimulation of separate chain receptors with NSO cells transfected with a control plasmid or a CD33-expressing plasmid.

Please replace the paragraph on page 12, lines 24-28 with the following paragraph:

Each component of the chimeric receptor was either PCR cloned or PCR assembled by standard techniques (PCR Protocols, Innis *et al* (1990) Academic Press Inc.) and sub-cloned in a cassette format into pBluecript KS+® (Stratagene), see Figure 1. Oligonucleotides (oligos) are described in Figure 2.

Please replace the paragraph on page 12, lines 30-35 with the following paragraph:

a) **Vl Cassette**

The variable region of the light chain of the human engineered antibody, hP67 (~~engineerd~~ engineered according to International Patent Specification WO91/09967) was PCR cloned with oligos S4503 and S4504. S4503 introduces a 5' Hind III site and S4504 a 3' Spe I site. The PCR product was restricted with Hind III and Spe I and subcloned into pBluescript KS+®.

Please replace the paragraph on page 13, lines 1-6 with the following paragraph:

b) **Vh Cassette**

The variable region of the heavy chain of the human engineered antibody, hP67 (engineered according to International Patent Specification WO91/0997) was PCR cloned with oligos S4501 and S4502. S4501 introduces a 5' Hind III site and S4502 a 3' Spe I site. The PCR product was restricted with Hind III and Spe I and subcloned into pBluescript KS+®.

Please replace the paragraph on page 13, lines 8-11 with the following paragraph:

c) **CD8* Spacer Cassette**

The CD8* spacer cassette was PCR assembled using overlapping oligos: S4881, S4882, S4883, S4884, S4885 and S4886. The PCR product was restricted with Spe I and Not I and subcloned into pBluescript KS+®.

Please replace the paragraph on page 13, lines 13-18 with the following paragraph:

d) **CD4 TM / CD4 Cassette**

The CD4 transmembrane and intracellular components were PCR cloned from human Leukocyte cDNA (Clonetech) with oligos S4499 and S4500. S4499 introduces a 5' Not I site and S4500 introduces a 3'_EcoR I and Sac I site. The PCR product was restricted with Not I and Sac I and subcloned into a pBluescript KS+®.

Please replace the paragraph on page 13, lines 26-27 with the following paragraph:

The PCR product was restricted with Not I and EcoR I and substituted for the CD4 TM/CD4 cassette in pBluescript KS+®.

Please replace the paragraph on page 13, lines 29-31 with the following paragraph:

All of the above cassettes were sequenced (Applied Biosystems, Taq DyeDeoxy Terminator Cycle Sequencing, Part Number 901497) in pBluescript KS+® prior to cloning into expression vectors.